Kristen E. Ashworth,Jessica Weisbrod,Brian G. Ballios
Abstract:Inherited retinal diseases (IRDs) are a large group of genetically and clinically diverse blinding eye conditions that result in progressive and irreversible photoreceptor degeneration and vision loss. To date, no cures have been found, although strides toward treatments for specific IRDs have been made in recent years. To accelerate treatment discovery, retinal organoids provide an ideal human IRD model. This review aims to give background on the development and importance of retinal organoids for the human-based in vitro study of the retina and human retinogenesis and retinal pathologies. From there, we explore retinal pathologies in the context of IRDs and the current landscape of IRD treatment discovery. We discuss the usefulness of retinal organoids in this context (as a patient-derived cell model for IRDs) to precisely understand the pathogenesis and potential mechanisms behind a specific IRD-causing variant of interest. Finally, we discuss the importance and promise of retinal organoids in treatment discovery for IRDs, now and in the future.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is **how to accelerate the discovery of treatments for Inherited Retinal Diseases (IRDs)**. Specifically, the paper explores the possibility of using retinal organoids as pre - clinical cell models for human IRDs. IRDs are a group of blinding eye diseases with diverse genetic and clinical manifestations, leading to progressive and irreversible photoreceptor degeneration and vision loss. Although some progress has been made in the treatment of specific IRDs in recent years, there is currently no cure. To accelerate the discovery of treatments, retinal organoids provide an ideal model that can be used to study human retinal development, retinal pathology, and the pathogenesis of IRDs, and to evaluate potential treatment candidates.
### Main content of the paper
1. **Background introduction**:
- **Definition and impact of IRDs**: IRDs are a group of blinding eye diseases with diverse genetic and clinical manifestations, leading to progressive and irreversible photoreceptor degeneration and vision loss. More than 300 gene variants related to IRDs have been discovered so far, but no cure has been found yet.
- **Treatment progress**: In recent years, gene therapy and cell therapy have been proposed as potential methods to repair and replace degenerated retinal cells in order to restore vision.
2. **Advantages of retinal organoids**:
- **Challenges in model selection**: Animal models have multiple limitations, including anatomical and electrophysiological differences, as well as differences in the expression and function of homologous retinal genes.
- **Characteristics of retinal organoids**: Retinal organoids are three - dimensional retinal structures cultured from human pluripotent stem cells (hPSCs), which can simulate human retinal development, cell fate determination, maturation, and gene expression. These organoids can be derived from patients with specific IRDs, providing personalized cell models.
3. **Genetic and clinical basis of IRDs**:
- **Genetic diversity**: The genetic patterns of IRDs are diverse, including autosomal dominant, autosomal recessive, and X - linked inheritance.
- **Clinical classification**: IRDs can be classified according to clinical features, such as early - or late - onset, non - syndromic or syndromic, stationary or progressive, etc.
4. **Current methods for IRD treatment discovery**:
- **Gene therapy**: By delivering healthy genetic material (DNA or RNA) to the diseased retina to restore the expression of gene products and visual function. For example, Luxturna is an FDA - approved gene therapy for treating RPE65 - related retinal dystrophy.
- **Cell therapy**: By transplanting donor cells to replace diseased cells in the host retina and restore visual function. This method is especially suitable for patients with advanced diseases, in which photoreceptors have degenerated significantly.
5. **Applications of retinal organoids**:
- **Studying retinal development and pathology**: Retinal organoids can be used to study human retinal development and the pathogenesis of IRDs.
- **Evaluating treatment candidates**: Retinal organoids can be used to screen and evaluate potential treatment candidates, accelerating the treatment discovery process.
### Conclusion
The paper emphasizes the importance and potential of retinal organoids in IRDs research, especially in accelerating treatment discovery. By using retinal organoids, researchers can more accurately understand the pathogenesis of specific IRDs and evaluate potential treatment strategies. This provides new hope for the future treatment of IRDs.